The shelf is changing. The interesting story isn't the new private-label line — those have been around for thirty years and most of them have been forgettable. The interesting story is the contract-manufacturer footnote on the back of the bottle.
Three of the largest North American retailers and at least two European chains have, in the last 18 months, dramatically upgraded their private-label beauty programs. They are not selling cheap imitations of prestige formulas anymore. They are selling — in some cases — better-formulated products than the brands those products sit next to, at a third of the price, made by the exact same contract manufacturer.
What changed
The contract-manufacturing tier consolidated. Five years ago, a retailer's private-label beauty program ran through a long tail of small CMOs with limited R&D capacity. Today, those small CMOs have been absorbed into a much smaller number of large, well-capitalized firms with serious labs, serious regulatory affairs functions, and serious ambitions.
These consolidated CMOs can — and do — formulate at parity with the brand-side teams they used to serve as vendors. They are willing to do it for retailers because retailers offer something brands do not: guaranteed shelf space, guaranteed reorder volume, and a margin structure that survives without the cost of marketing.
We can ship a better serum than the $80 prestige brand on the same shelf. We are happy to. They were our customer last year.
The consequence for brands
The mid-tier prestige brand — $40 to $90 price point, no defensible IP, mid-cap retail distribution — is the most exposed segment in beauty right now. A private-label competitor with a credible formulation and 60 percent of the price point is no longer a curiosity. In several categories, it is the third-most-shopped item on the shelf.
The brands that will survive this in the mid-tier are the ones with one of three things: genuine ingredient or formulation IP, a brand the customer would still pay a premium for in a blind comparison, or a distribution channel the retailer cannot replicate.
Many brands have none of these.
What we are watching
- Whether the largest US drug chain's beauty program crosses the $1B private-label revenue line — widely expected this fiscal year.
- Whether a major European chain extends its private-label fragrance program into licensed celebrity scents, which would mark a meaningful escalation.
- Whether contract manufacturers begin to license their proprietary actives to retailers directly, which would close off a meaningful R&D advantage for brand-side customers.
This is the quiet structural shift of the next five years. The brands that are watching it are repositioning now. The brands that are not are still treating their nearest shelf neighbor as the competition — when the real competition is the unbranded bottle two shelves over.